FY2025 · ended Dec 31, 2025 · Revenue $61.24M, +11.1% YoY · Filed Mar 26, 2026
Journey Medical Corp (DERM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $61.2 million and a net loss of $11.4 million. As of Jun 30, 2026 it held $25.6 million in cash and investments and $25.5 million in total debt.
Revenue (TTM)
$66.85M
+20.7% vs year-ago TTM
Net income (TTM)
$-6.10M
+30.1% vs year-ago TTM
Operating cash flow (TTM)
$-7.49M
-176.9% vs year-ago TTM
Free cash flow
$-24.13M
-10152.9% vs prior year
EPS (TTM)
$-0.23
+42.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$102,000
as of Jun 30, 2026
Operating margin
-4.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DERM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Scottsdale, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1867066
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $61.2M | $55.1M | $59.7M | $71.0M | $63.1M |
| Operating income | -$8.2M | -$13.7M | -$2.1M | -$27.5M | -$34.9M |
| Net income | -$11.4M | -$14.7M | -$3.9M | -$29.6M | -$44.0M |
| Diluted EPS | -$0.47 | -$0.72 | -$0.21 | -$1.69 | -$4.32 |
| Operating cash flow | -$12.4M | -$9.1M | $5.2M | -$13.5M | -$2.2M |
| Free cash flow | — | -$24.1M | $240,000 | -$33.5M | — |
| Total assets | $94.6M | $80.2M | $76.8M | $105.2M | $97.3M |
| Total liabilities | $62.7M | $60.2M | $56.5M | $88.2M | $55.2M |
| Stockholders' equity | $31.9M | $20.1M | $20.4M | $17.0M | $42.0M |
| Cash and investments | $24.1M | $20.3M | $27.4M | $32.0M | $49.1M |
| Total debt | $25.4M | $25.1M | $14.7M | $28.0M | $98,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Other events
|
Apr 21, 2026 | Apr 21, 2026 |
All 229 Journey Medical Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.